PET-CT for Small Cell — Lung Cancer Staging

NCCN and ESMO guidelines recommend PET-CT as part of the standard staging workup for small cell lung cancer. Where it cannot be done — for example, if you have a condition that prevents you lying still for the scan, or if the scan is not available locally — your oncologist will stage using other available imaging. But where PET-CT can be arranged, it is preferred because it detects spread that CT alone may miss, and an accurate stage matters for the treatment decision that follows.

Limited-stage small cell lung cancer is treated with chemotherapy and radiotherapy given together, usually over several weeks. This combination is more intensive than chemotherapy alone but aims for greater long-term disease control. If your disease responds well, your oncologist may also discuss low-dose radiation to the brain — prophylactic cranial irradiation — because small cell lung cancer has a tendency to spread there even when it is not detectable at the time of staging. Your oncologist will explain whether that applies to you.

The stage determined at diagnosis guides your initial treatment plan. However, small cell lung cancer can change quickly, and if there is a significant delay before treatment begins, your team may want to review imaging again before proceeding. If you are already in treatment and the disease is not responding, your oncologist will reassess the picture at that point. The initial staging is a starting point — not a label that prevents your team from re-evaluating if the situation changes.

Yes. Extensive-stage disease responds to systemic treatment in a proportion of patients, often substantially at first. Chemotherapy can reduce the disease burden and improve symptoms, and for patients whose tumours meet certain criteria, immunotherapy may be added. The goal of treatment shifts from eliminating contained disease to managing spread and preserving quality of life. Your oncologist will explain what the treatment is expected to achieve for your specific situation.

Bone marrow biopsy was part of small cell lung cancer staging in the past, when imaging was less accurate. Current NCCN guidance does not routinely require it when a PET-CT has been done, because PET-CT can detect bone marrow involvement directly. Your oncologist may still recommend it in specific circumstances — for example, if the PET-CT result is inconclusive or could not be completed. If it has not been mentioned, ask your team whether it is relevant to your case.

PET-CT for small cell lung cancer staging is coordinated through CION's partner imaging centres. Your CION oncologist reviews those results alongside your biopsy report and brain MRI to determine your stage and agree a treatment plan. Chemotherapy and immunotherapy are given as day care at CION centres. If you have already had imaging done elsewhere, bring the reports and image discs to your first appointment so they can be reviewed in full before any decisions are made.